Merrill Lynch (NYSE:MER): Positive feedback from analysts
Source: http://notablecalls.blogspot.com/2008/07/merrill-lynch-nysemer-positive-feedback.htmlPosted on Tuesday, July 29th, 2008 | In Market Commentary
- Oppenheimer’s Meredith Whitney notes this would reduce MER’s CDOs exposure by $11.1 billion. While MER has significantly diluted existing shareholders, they applaud this purging of assets as an attempt to cut its losses and focus on stabilizing its platform and righting the franchise towards growth. While MER’s stock still sells at a premium to book value and is expensive in firm’s opinion, they believe the stock is getting closer to fairly valued levels as now the hardest work is behind the company.
- Deutsche Bank notes the move increases shares outstanding by est. 38% and reduces est. run-rate EPS from $4/sh. to $2.80/sh but also eliminates most of the worst vintage CDOs, gets cash up front from monolines (vs. waiting 20-40 yrs.), and keeps book value around $22/share. DB is lowering their price target from $31 to $28 but keeping their Hold rating given an inexpensive valuation.
The good news is that the actual sales can give confidence that it is finally selling assets vs. merely marking them to market. Merrill is also getting ahead of others in getting money from monolines.
They apply a target multiple of 1.2x to their 2009E book value of $23.
- Goldman Sachs thinks it was undoubtedly a bitter pill to swallow, but they believe management’s decision to finally sell the majority of its ABS CDO portfolio and write-off its monoline exposure was the right thing to do in order to move the firm forward. Nonetheless, these actions come at a very high cost to existing investors as outstanding shares increase by 38% under the “if converted” method (assuming no exercise of the over-allotment option). Although painful, the firm believes putting these issues largely behind it will better enable the firm to focus on existing business opportunities in the marketplace.
Merrill Lynch currently trades at 1.1x its pro forma if-converted book value of roughly $22. GSCO’s new $28.50 six month price target assumes the stock will trade at 1.3x its pro forma if-converted book value in six months.
- Citigroup says that in their view the Merrill franchise has a tremendous amount of earnings power that can be unleashed over time through execution. While the real promise of the new management team at Merrill is the potential to unlock this earnings power, the legacy assets proved to be a year-long detour, but that is now behind us.
This is the first large-scale CDO transaction that is not a distressed sale. Industry participants will likely mark super-senior CDO assets with 2006 & 2007 vintage collateral down to the $0.22 range. Including the financing, Merrill took assets with a carrying value of $0.36 and wrote them down to $0.22, and transferred the risk of declines down to $0.17 to a 3rd party.
Reiterates Buy and $45 tgt (down from $65 due to dilution) as they expect the sale of highly illiquid mortgage related assets to be a catalyst to refocus on the earnings power of the Merrill
franchise. The overhang that has plagued MER for over a year has finally been removed. Furthermore, the capital raised enhances the quality of Merrill’s equity base by significantly reducing the preferred component in exchange for straight common equity. MER is trading at 1.1x book despite the credibility of book value being materially higher post reducing the CDO exposure.
Notablecalls: So that’s why MER was schmeissed over the past couple of days. I think the stock will see a bounce on this. Trading around book value and around 10x FY09 ests is where people will likely come in to buy the common.
It’s all about survival these days and looks like MER has made it.
Only downside to the story can now come from earnings. Let’s face it – we don’t know what’s MER’s real earnings power is.
Last 5 posts by Notable Calls
- Petroquest Energy (NYSE:PQ): Compelling Valuation with Near-Term Catalysts; Upgrading to Overweight - J.P. Morgan - October 29th, 2009
- 15% correction coming in SP500? - October 21st, 2009
- Boeing (NYSE:BA): Downgraded to Underweight at Morgan Stanley, target to $43 - October 20th, 2009
- Par Pharmaceuticals (NYSE:PRX): Upgraded to Overweight at Barclays; target raised to $30 - October 15th, 2009
- Wyndham Worldwide (NYSE:WYN): Upgraded to Buy at Goldman Sachs; $26 target established - October 7th, 2009
![]() About Notable Calls (http://notablecalls.blogspot.com/)
Notable Calls is composed by an anonymous Wall Street professional who, every morning before market open, collects actionable analyst notes and offers an insightful personal response. |



